[go: up one dir, main page]

EP1360496A4 - Methodes et reactifs destines a l'isolement rapide et efficace de cellules cancereuses circulantes - Google Patents

Methodes et reactifs destines a l'isolement rapide et efficace de cellules cancereuses circulantes

Info

Publication number
EP1360496A4
EP1360496A4 EP02806645A EP02806645A EP1360496A4 EP 1360496 A4 EP1360496 A4 EP 1360496A4 EP 02806645 A EP02806645 A EP 02806645A EP 02806645 A EP02806645 A EP 02806645A EP 1360496 A4 EP1360496 A4 EP 1360496A4
Authority
EP
European Patent Office
Prior art keywords
reagents
rapid
methods
cancer cells
circulating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02806645A
Other languages
German (de)
English (en)
Other versions
EP1360496A1 (fr
Inventor
Leon W M M Terstappen
Galla Chandra Rao
Shawn Mark O'hara
Paul A Liberti
Steven Gross
Gerald Doyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunivest Corp
Original Assignee
Immunivest Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunivest Corp filed Critical Immunivest Corp
Publication of EP1360496A1 publication Critical patent/EP1360496A1/fr
Publication of EP1360496A4 publication Critical patent/EP1360496A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/549—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic with antigen or antibody entrapped within the carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Electrochemistry (AREA)
  • Power Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP02806645A 2001-02-16 2002-02-19 Methodes et reactifs destines a l'isolement rapide et efficace de cellules cancereuses circulantes Withdrawn EP1360496A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26885901P 2001-02-16 2001-02-16
US268859P 2001-02-16
US26927001P 2001-02-20 2001-02-20
US26927101P 2001-02-20 2001-02-20
US269270P 2001-02-20
US269271P 2001-02-20
PCT/US2002/005233 WO2003065042A1 (fr) 2001-02-16 2002-02-19 Methodes et reactifs destines a l'isolement rapide et efficace de cellules cancereuses circulantes

Publications (2)

Publication Number Publication Date
EP1360496A1 EP1360496A1 (fr) 2003-11-12
EP1360496A4 true EP1360496A4 (fr) 2005-03-09

Family

ID=27670560

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02806645A Withdrawn EP1360496A4 (fr) 2001-02-16 2002-02-19 Methodes et reactifs destines a l'isolement rapide et efficace de cellules cancereuses circulantes

Country Status (8)

Country Link
EP (1) EP1360496A4 (fr)
JP (1) JP2005516217A (fr)
KR (1) KR20030080002A (fr)
AU (2) AU2002306561A2 (fr)
BR (1) BR0207290A (fr)
CA (1) CA2438112A1 (fr)
IL (1) IL157256A0 (fr)
WO (1) WO2003065042A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
EP1597353B1 (fr) 2003-02-27 2010-11-24 Veridex, LLC Cellules tumorales circulantes (ctc): evaluation precoce du temps d'evolution, de la survie et de la reaction aux therapies des patients cancereux metastasiques
JP4629675B2 (ja) * 2003-09-18 2011-02-09 ベリデックス・リミテッド・ライアビリティ・カンパニー オペレーター不要のプログラム可能な試料調製および分析システム
WO2005085845A1 (fr) * 2004-03-03 2005-09-15 Universidad De Salamanca Detection multidimensionnelle de phenotypes aberrants dans des cellules neoplasiques pour surveiller des niveaux minimum de maladies a l'aide de la cytometrie de flux
JP4798801B2 (ja) * 2004-10-06 2011-10-19 ウェルスタット バイオロジクス コーポレイション 循環する癌細胞におけるＨｅｒ−２／ｎｅｕタンパク質のレベルの上昇の検出および処置
US7595380B2 (en) * 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
CN1772303A (zh) * 2005-10-25 2006-05-17 朱宏 恶性肿瘤磁热疗用纳米磁粉－抗体靶向药物
US7842465B2 (en) * 2006-01-17 2010-11-30 Palo Alto Research Center Incorporated Immunocytostaining methods for enhanced dye ratio discrimination in rare event detection
CA2642542C (fr) * 2006-02-16 2012-09-25 Ventana Medical Systems, Inc. Reactifs et procedes pour le pronostic et la stadification pathologique d'un cancer
EP2007874A4 (fr) * 2006-03-13 2009-06-10 Veridex Llc Propagation de cellules primaires
CA2647743A1 (fr) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection de recepteurs steroidiens sur les cellules carcinomateuses circulantes et leur traitement
CA2647843A1 (fr) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection de proteines dans des cellules neoplasiques en circulation
EP2027470B1 (fr) * 2006-06-02 2012-11-21 Pfizer Products Inc. Analyse de cellules tumorales circulantes
EP2041299A4 (fr) 2006-07-14 2010-01-13 Aviva Biosciences Corp Procedes et compositions servant a detecter des cellules rares dans un echantillon biologique
US7828968B2 (en) 2007-08-30 2010-11-09 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
US8110101B2 (en) 2007-08-30 2012-02-07 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
RU2389024C1 (ru) * 2008-12-02 2010-05-10 Александр Валентинович Шишкин Способ исследования клеток с помощью иммунологического биочипа
US20120004289A1 (en) * 2009-03-06 2012-01-05 The Johns Hopkins University Annexin a11 and associated genes as biomarkers for cancer
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
ES2557914T3 (es) 2009-03-24 2016-01-29 Biocept, Inc. Dispositivos y métodos de captura y análisis de células
DE102009047146B4 (de) * 2009-11-25 2012-07-19 Ulrich Pachmann Verfahren zum Vorhersagen des Ansprechens einer Tumorerkrankung auf eine therapeutische Maßnahme
US9612236B2 (en) 2010-06-17 2017-04-04 Koninklijke Philips N.V. Multi epitope assay
CA2804269A1 (fr) 2010-07-07 2012-01-12 The Regents Of The University Of Michigan Diagnostic et traitement du cancer du sein
US20120252038A1 (en) * 2011-04-01 2012-10-04 Chianese David A Steroid receptor assays
KR101988600B1 (ko) * 2011-06-29 2019-06-12 가부시키가이샤 엘에스아이 메디엔스 비특이 반응 억제제, 비특이 반응 억제 방법 및 키트
EP2786151B1 (fr) 2011-11-29 2019-07-03 F.Hoffmann-La Roche Ag Methodes d'analyse cancer de la prostate
US20150044224A1 (en) * 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
CN102914650B (zh) * 2012-06-14 2014-11-05 北京大成生物工程有限公司 神经元特异性烯醇化酶定量检测试剂盒及其制备方法与应用
CN105209489B (zh) 2013-03-05 2019-06-14 得克萨斯州大学系统董事会 针对间质和上皮-间质转化的循环肿瘤细胞的特异性检测工具
CN104561246B (zh) * 2013-10-18 2018-06-15 深圳先进技术研究院 血液中循环癌细胞的检测信号放大的方法与试剂盒
JP6582486B2 (ja) * 2015-03-27 2019-10-02 コニカミノルタ株式会社 血液中の稀少細胞検出方法
US10758906B2 (en) 2016-02-18 2020-09-01 Genobio, Inc. Cell separation chip and system
KR101723072B1 (ko) 2016-12-29 2017-04-05 주식회사 지노바이오 셀 분리 시스템
KR101723082B1 (ko) 2016-12-29 2017-04-05 주식회사 지노바이오 셀 분리 장치
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
CN110669823B (zh) 2018-07-03 2022-05-24 中国医学科学院肿瘤医院 一种同时检测多种肝癌常见突变的ctDNA文库构建和测序数据分析方法
JP6935883B2 (ja) * 2018-07-13 2021-09-15 五稜化薬株式会社 蛍光画像診断の前処理方法
US20240295549A1 (en) * 2020-08-07 2024-09-05 Vital Biosciences Inc. Multiplexed analyte detection
CN114958748B (zh) * 2022-04-24 2024-02-13 东北大学 高效捕获和无损释放循环肿瘤细胞的纳米磁性亲和材料
CN118741012B (zh) * 2024-09-02 2024-12-24 浙江芯劢微电子股份有限公司 一种视频信号的滤波方法、电路和计算机可读存储介质

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041613A1 (fr) * 1998-02-12 1999-08-19 Immunivest Methodes et reactifs pour l'isolation rapide et efficace de cellules cancereuses circulantes
WO1999058978A2 (fr) * 1998-05-11 1999-11-18 The University Of Nottingham Marqueurs de tumeurs
US5993829A (en) * 1987-04-23 1999-11-30 Bystryn; Jean-Claude Anti-cancer vaccine
WO2000047998A1 (fr) * 1999-02-10 2000-08-17 Cell Works Inc. Caracterisation de classes de cellules cancereuses circulantes isolees a partir de fluides corporels et methodes d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512657A (en) * 1988-12-12 1996-04-30 Bainbridge Sciences, Inc. Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases
DE69333448D1 (en) * 1992-07-22 2004-04-15 Univ Princeton P53 impfstoff
US5545527A (en) * 1994-07-08 1996-08-13 Visible Genetics Inc. Method for testing for mutations in DNA from a patient sample
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
AU6289699A (en) * 1998-10-05 2000-04-26 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993829A (en) * 1987-04-23 1999-11-30 Bystryn; Jean-Claude Anti-cancer vaccine
WO1999041613A1 (fr) * 1998-02-12 1999-08-19 Immunivest Methodes et reactifs pour l'isolation rapide et efficace de cellules cancereuses circulantes
WO1999058978A2 (fr) * 1998-05-11 1999-11-18 The University Of Nottingham Marqueurs de tumeurs
WO2000047998A1 (fr) * 1999-02-10 2000-08-17 Cell Works Inc. Caracterisation de classes de cellules cancereuses circulantes isolees a partir de fluides corporels et methodes d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E.RACILA ET AL: "Detection and characterization of carcinoma cells in the blood", PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 95, 1 April 1998 (1998-04-01) - 1998, pages 4589 - 4594, XP002313397 *
See also references of WO03065042A1 *

Also Published As

Publication number Publication date
AU2008249153B2 (en) 2012-05-10
KR20030080002A (ko) 2003-10-10
BR0207290A (pt) 2005-06-07
WO2003065042A1 (fr) 2003-08-07
AU2002306561A2 (en) 2003-09-02
JP2005516217A (ja) 2005-06-02
CA2438112A1 (fr) 2003-08-07
EP1360496A1 (fr) 2003-11-12
IL157256A0 (en) 2004-02-19
AU2008249153A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
EP1360496A4 (fr) Methodes et reactifs destines a l'isolement rapide et efficace de cellules cancereuses circulantes
EP1434887A4 (fr) Procede d'isolation de cellules et utilisation correspondante
NO990110D0 (no) Prefabrikert dusjmodul og fremgangsmÕte for konstruksjon av dusj
DK1003532T3 (da) Tarmcellers absorption af mineraler
EA200000274A3 (ru) Способы получения и промежуточные соединения для получения противораковых соединений
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
ID20191A (id) Rancang bangun reaktor penghantar ion electrolit bentuk padat
AU2002258941A1 (en) Methods of enhancing cell responsiveness
NO20011303L (no) Fremgangsmåter for nukleinsyreoppformering og sekvensering
IL146086A0 (en) Method of solar cell external interconnection and solar cell panel made thereby
DK1148875T3 (da) Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer
AU5599401A (en) Method of business analysis
EP1546719A4 (fr) Isolation et identification de cellules t
EP1389970A4 (fr) Compositions et methodes permettant un double ciblage d'infections virales et de cellules cancereuses
AU2001236734A1 (en) Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies
GB9808264D0 (en) Biochemical devices and their methods of manufacture
GB0416516D0 (en) Method of transducing es cells
NO20024879L (no) Fremgangsmåte ved påvisning av celler
FI20011940L (fi) Vaahdotusmekanismi ja -kenno
AU2409602A (en) Method of testing anticancer agent-sensitivity of tumor cells
NO20006537D0 (no) Fremgangsmåte og anordning ved bunndetektor
AU2001292468A1 (en) Methods and means of rna analysis
AU2003260131A8 (en) Assays for the detection of biliverdin in birds and reptiles
AUPQ825300A0 (en) Method of sentence analysis
AU2003217743A8 (en) Magnetic immobilization of cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DOYLE, GERALD

Inventor name: GROSS, STEVEN

Inventor name: LIBERTI, PAUL, A.

Inventor name: O'HARA, SHAWN, MARK

Inventor name: RAO, GALLA, CHANDRA

Inventor name: TERSTAPPEN, LEON, W., M., M.

17P Request for examination filed

Effective date: 20040112

A4 Supplementary search report drawn up and despatched

Effective date: 20050124

17Q First examination report despatched

Effective date: 20050531

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080619